Explore 3 Stock Ideas & Industry Insights Download Free Report

Company price
0.7495 USD 0.03 ( 4.37%)
Last update at 2026-11-20T21:00:00Z
VOLUME
25400
Market Cap
8.23M

Momentum Score

…

NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines. The company, through its technology, is developing ProTides medicines to overcome the limitations of nucleoside analogs and generate much higher concentrations of anti-cancer metabolites in cancer cells. Its pipeline includes NUC-3373, a chemical entity derived from the nucleoside analog 5-fluorouracil that is in Phase 1b/2 study in patients with metastatic colorectal cancer, Phase 2 clinical trial for the second-line treatment of patients with advanced colorectal cancer, and Phase 1b/2 modular clinical trial for patients with advanced solid tumors and lung cancer. It is also developing NUC-7738, a ProTide transformation of 3'-deoxyadenosine, which is in the Phase 2 part of a Phase 1/2 clinical trial for patients with advanced solid tumors. The company has an assignment, license, and collaboration agreement with Cardiff ProTides Ltd to discover, drug design, and in vitro screen purine and pyrimidine-based nucleosides as potential drug candidates. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017. NuCana plc was incorporated in 1997 and is headquartered in Edinburgh, the United Kingdom.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.70
Low
0.79
High
52 Week Price Range
3.40
Low
23.75
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
0.72
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
0.03
ROE
-103.51%
Net Debt
-16.83M
ROCE
-258.49%
Diluted EPS TTM
-16.22

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -38.45M -47.80M -36.17M -25.65M -18.06M
Minority interest - - - 0.00M 0.00M
Net income -32.02M -40.53M -30.68M -21.41M -13.84M
Selling general administrative 7.29M 8.53M 7.05M 5.95M 5.18M
Gross profit - - - 0.00M 0.00M
Reconciled depreciation 0.73M 0.94M 0.89M 0.72M 0.37M
Ebit -39.12M -47.91M -36.42M -26.70M -24.93M
Ebitda -47.58M -41.88M -28.59M -23.94M -24.56M
Depreciation and amortization -8.46M 6.03M 7.83M 2.76M 0.37M
Non operating income net other - - - 0.00M 0.00M
Operating income -39.12M -47.91M -36.42M -26.70M -19.13M
Other operating expenses 43.72M 45.36M 32.95M 25.68M 22.03M
Interest expense -9.86M 4.98M 6.70M 0.99M 0.00M
Tax provision -6.43M -7.27M -5.49M -4.24M -4.22M
Interest income 0.67M 0.10M 0.25M 1.05M 1.06M
Net interest income 0.67M 0.10M 0.25M 1.05M 1.06M
Extraordinary items - - - 0.00M 0.00M
Non recurring - - - 0.00M 0.00M
Other items - - - 0.00M 0.00M
Income tax expense -6.43M -7.27M -5.49M -4.24M -4.22M
Total revenue 0.00M 0.00M 0.00M 0.00M 0.00M
Total operating expenses 43.72M 45.36M 32.95M 25.68M 22.03M
Cost of revenue - - - 0.00M 0.00M
Total other income expense net 0.67M 0.10M 0.25M 1.05M 2.90M
Discontinued operations - - - 0.00M 0.00M
Net income from continuing ops -32.02M -40.53M -30.68M -21.41M -13.84M
Net income applicable to common shares -32.02M -40.53M -30.68M -21.41M -13.84M
Preferred stock and other adjustments - - - 0.00M 0.00M
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 27.81M 58.25M 77.47M 107.79M 70.27M
Intangible assets 2.13M 2.37M 2.41M 4.75M 3.96M
Other current assets - 2.68M 3.15M 3.80M 4.12M
Total liab 12.92M 19.75M 11.93M 8.56M 6.75M
Total stockholder equity 14.89M 38.50M 65.55M 99.23M 63.52M
Deferred long term liab - - - - 0.00M
Other current liab 9.10M 14.26M 9.68M 5.61M 3.50M
Common stock 2.11M 143.20M 143.14M 142.94M 80.84M
Capital stock 2.11M 143.20M 2.09M 2.05M 1.30M
Retained earnings -207.71M -180.57M -149.73M -110.59M -80.06M
Other liab - 0.05M 0.05M 0.05M 0.03M
Good will - - - - 0.00M
Other assets - 0.10M 2.60M 0.04M 0.05M
Cash 17.23M 41.91M 60.26M 87.36M 51.96M
Total current liabilities 12.68M 19.31M 11.72M 8.15M 6.18M
Net debt -16.83M -41.27M -59.89M -86.71M -51.16M
Short term debt 0.21M 0.24M 0.21M 0.28M 0.27M
Short long term debt - - - - 0.00M
Short long term debt total 0.40M 0.64M 0.37M 0.65M 0.81M
Other stockholder equity 141.31M 219.07M 215.27M 209.82M 143.58M
Property plant equipment - 0.87M 0.85M 1.19M 1.11M
Total current assets 25.02M 54.92M 71.61M 101.81M 65.15M
Long term investments - - - - 0.00M
Net tangible assets - 36.14M 63.14M 94.48M 59.56M
Short term investments - - - - 0.00M
Net receivables 5.83M 10.32M 11.35M 14.45M 13.19M
Long term debt - - - - 0.00M
Inventory - - -3.15M - 0.00M
Accounts payable 3.38M 4.80M 1.83M 2.26M 2.41M
Total permanent equity - - - - 0.00M
Noncontrolling interest in consolidated entity - - - - 0.00M
Temporary equity redeemable noncontrolling interests - - - - 0.00M
Accumulated other comprehensive income 79.17M 75.87M 72.14M 66.89M 62.74M
Additional paid in capital - - - - 0.00M
Common stock total equity - - - 2.05M 1.30M
Preferred stock total equity - - - - 0.00M
Retained earnings total equity - - - - 0.00M
Treasury stock - - - - -0.34M
Accumulated amortization - - - - 0.00M
Non currrent assets other - - 2.54M - 1.11M
Deferred long term asset charges - - - - 0.00M
Non current assets total 2.79M 3.33M 5.86M 5.99M 5.12M
Capital lease obligations 0.40M 0.64M 0.37M 0.65M 0.81M
Long term debt total - - - - 0.54M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments 0.12M -3.56M -1.31M -0.14M -0.65M
Change to liabilities 2.97M -0.43M -0.15M -0.04M 1.33M
Total cashflows from investing activities 0.12M -3.56M -1.31M -0.14M -0.65M
Net borrowings -0.23M -0.30M -0.30M -0.20M -0.20M
Total cash from financing activities -0.16M -0.10M 61.80M -0.05M 0.21M
Change to operating activities 0.75M 4.52M 2.10M -2.06M 2.14M
Net income -32.02M -40.53M -30.68M -21.41M -13.84M
Change in cash -18.35M -27.09M 35.39M -25.01M -9.73M
Begin period cash flow 60.26M 87.36M 51.96M 76.97M 86.70M
End period cash flow 41.91M 60.26M 87.36M 51.96M 76.97M
Total cash from operating activities -23.16M -23.82M -21.62M -23.83M -12.22M
Issuance of capital stock 0.07M 0.00M 66.58M 0.12M 0.00M
Depreciation 0.73M 0.94M 0.89M 0.72M 0.37M
Other cashflows from investing activities 0.64M -2.50M 0.32M 1.12M 0.97M
Dividends paid - - - 0.00M 0.00M
Change to inventory - - - 0.00M 0.00M
Change to account receivables - - - 0.00M 0.00M
Sale purchase of stock - - - 0.12M 0.21M
Other cashflows from financing activities 0.12M 0.20M -4.48M 0.03M 0.21M
Change to netincome 4.41M 11.67M 6.22M -1.04M -2.23M
Capital expenditures 0.52M 1.06M 1.63M 1.26M 1.62M
Change receivables - - - 0.00M 0.00M
Cash flows other operating - - - 0.00M 0.00M
Exchange rate changes - - - 0.00M 0.00M
Cash and cash equivalents changes - - - 0.00M 0.00M
Change in working capital 3.72M 4.09M 1.95M -2.10M 3.47M
Stock based compensation 4.89M 6.66M 4.30M 3.23M 1.79M
Other non cash items 5.95M 12.28M 7.41M -0.02M 0.20M
Free cash flow -23.68M -24.89M -23.25M -25.09M -13.85M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to EBITDA (x)
NCNA
NuCana PLC
0.03
4.37%
0.75 - - - 0.63 0.31
NVO
Novo Nordisk A/S
-1.06
2.73%
37.81 41.58 31.15 2.13 32.99 4.70
VRTX
Vertex Pharmaceuticals Inc
-5.64
1.08%
515.02 30.22 24.27 10.36 6.50 24.66
REGN
Regeneron Pharmaceuticals Inc
-
-%
920.69 29.07 20.12 7.57 3.82 19.42
ARGNF
argenx SE
-
-%
965.00 45.77 31.25 13.84 7.12 36.06

Profile*

NuCana PLC

NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines. The company, through its technology, is developing ProTides medicines to overcome the limitations of nucleoside analogs and generate much higher concentrations of anti-cancer metabolites in cancer cells. Its pipeline includes NUC-3373, a chemical entity derived from the nucleoside analog 5-fluorouracil that is in Phase 1b/2 study in patients with metastatic colorectal cancer, Phase 2 clinical trial for the second-line treatment of patients with advanced colorectal cancer, and Phase 1b/2 modular clinical trial for patients with advanced solid tumors and lung cancer. It is also developing NUC-7738, a ProTide transformation of 3'-deoxyadenosine, which is in the Phase 2 part of a Phase 1/2 clinical trial for patients with advanced solid tumors. The company has an assignment, license, and collaboration agreement with Cardiff ProTides Ltd to discover, drug design, and in vitro screen purine and pyrimidine-based nucleosides as potential drug candidates. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017. NuCana plc was incorporated in 1997 and is headquartered in Edinburgh, the United Kingdom.

3 Lochside Way, Edinburgh, United Kingdom, EH12 9DT

44 13 1357 1111

25

Name Title Year Born
Mr. Hugh Stephen Griffith Founder, CEO & Exec. Director 1968
Mr. Donald Munoz Chief Financial Officer 1969
Mr. David Harrison Head of Translational Medicine 1960
Dr. Jeffrey D. Bloss F.A.C.O.G., M.D. Chief Medical Officer 1957
Prof. Christopher B. Wood FRCS, M.D., Ph.D. Chief Medical Officer 1946
Ms. Theresa Bruce Sr. VP of Clinical Operations NA
Ms. Elisabeth Oelmann Sr. VP of Medical & Clinical Devel. NA
Martin Quinn Company Sec. NA
Mr. Hugh Stephen Griffith Founder, CEO & Executive Director 1968
Dr. Jeffrey D. Bloss F.A.C.O.G., M.D. Chief Medical Officer 1958

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…